Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2002-03-27 | Joseph M. Davie (age 62) has served as a director of Targeted Genetics since October 2000. Dr. Davie was employed by Biogen, Inc., a biopharmaceutical company, from 1993 to 2000, most recently serving as senior vice president, research. |
| 2003-03-27 | Joseph M. Davie (age 63) has served as a director of Targeted Genetics since October 2000. The members of the compensation committee are Jack L. Bowman (chairman), Joseph M. Davie and Mark P. Richmond, each of whom are nonemployee directors. |
| 2004-03-24 | Joseph M. Davie (age 64) has served as a director since October 2000. He is a member of the compensation committee and nominating committee. The compensation committee members are Jack L. Bowman (chairman), Joseph M. Davie and Mark P. Richmond. The nominating committee includes all directors except Ms. Parker. |
| 2005-04-14 | Joseph M. Davie (age 65) has served as a director of Targeted Genetics since October 2000. ... Dr. Davie was employed by Biogen, Inc., a biopharmaceutical company, from 1993 to 2000, most recently serving as senior vice president, research. ... The Compensation Committee also administers our various incentive compensation and benefit plans, including our stock option plans, and recommends the establishment of policies relating to our incentive compensation and benefit plans. The members of this committee are Jack L. Bowman (chairman), Joseph M. Davie and Mark H. Richmond, each of whom are independent directors. |
| 2006-03-29 | Joseph M. Davie (age 66) has served as a director since October 2000. He serves on the Compensation Committee and the Nominating and Corporate Governance Committee. The Board of Directors has determined that Dr. Davie is an independent director. |
| 2007-04-02 | Joseph M. Davie has served as a director since October 2000. He serves on the Audit Committee and Compensation Committee (Chairman). Director Summary Compensation Table for Fiscal Year 2006 shows total compensation of $27,931. |
| 2007-11-21 | Joseph M. Davie |
| 2008-03-28 | Joseph M. Davie has served as a director since October 2000. ... Director Compensation Table for Fiscal Year 2007 ... Joseph M. Davie Fees Earned $33,625, Stock Awards $19,561, Option Awards $2,644, Total $55,830 ... Committees: Compensation Committee, Nominating and Corporate Governance Committee. |
| 2009-04-06 | Joseph M. Davie has served as a director of Targeted Genetics since October 2000. The Board has determined that Dr. Davie is an independent director. He serves on the Compensation Committee and the Nominating and Corporate Governance Committee. |
| Filing Date | Source Excerpt |
|---|---|
| 2004-04-22 | Dr. Davie was the Senior Vice President of Research at Biogen, Inc., a biotechnology company. He held senior positions at G.D. Searle and Co., and academic positions at Washington University School of Medicine. He has a Ph.D. and M.D. |
| 2005-04-20 | Dr. Davie received his M.D. from the Washington University School of Medicine and his Ph.D. from Indiana University. |
| 2006-04-13 | Dr. Davie received his M.D. from the Washington University School of Medicine and his Ph.D. from Indiana University. |
| 2007-04-13 | Dr. Davie was professor and head of the Department of Microbiology and Immunology at Washington University School of Medicine from 1975 to 1987. He currently serves as a director of Targeted Genetics Corporation and CV Therapeutics, Inc. as well as several privately-held companies. Dr. Davie received his A.B., M.A. and Ph.D. in bacteriology from Indiana University and his M.D. from Washington University School of Medicine. |
| 2008-04-11 | Dr. Davie was the Senior Vice President of Research at Biogen, Inc. and held senior positions at pharmaceutical companies; received A.B., M.A., Ph.D. in bacteriology and M.D. |
| 2009-04-17 | Dr. Davie received his A.B., M.A. and Ph.D. in bacteriology from Indiana University and his M.D. from Washington University School of Medicine. |
| 2010-04-16 | Dr. Davie received his A.B., M.A. and Ph.D. in bacteriology from Indiana University and his M.D. from Washington University School of Medicine. We believe that Dr. Davie’s qualifications to serve on our board include his extensive experience and knowledge of oncology drug development as well as his experience as a director of other public companies. |
Data sourced from SEC filings. Last updated: 2026-02-03